Alvotech Announces $125M Equity Offering Amid Regulatory and Balance Sheet Strain

What happened

Alvotech has commenced a $125 million public offering of ordinary shares, with an underwriter option for an additional 15%, to shore up its balance sheet as it navigates FDA manufacturing remediation and commercial launches. The capital raise comes on the heels of a ~65% stock price decline over the past year, reflecting the November 2025 AVT05 complete response letter that severely cut 2025 guidance. Despite the company's narrative of funding growth, the offering is a dilutive move that underscores its precarious financial position: negative equity of $177 million, ~$1.1 billion in secured debt, and negative free cash flow of $36.6 million in 9M 2025. Existing shareholders will absorb further dilution, and the proceeds are likely earmarked for facility remediation and working capital rather than value-creating investment. The offering does not resolve the core issue—recurring FDA quality deficiencies at a single-site facility—and may signal that management lacks confidence in near-term cash flow generation.

Implication

This equity raise, while providing a cash buffer, does not fix Alvotech's structural challenges: a single FDA-challenged facility, high leverage, and uncertain cash flow visibility. Longer-term investors should demand evidence of successful AVT05 remediation and sustained free cash flow before considering entry. The offering increases the likelihood of further dilutive events if commercial launches underperform or additional regulatory setbacks occur, widening the gap to our attractive entry point of $3.75.

Thesis delta

The $125M equity offering shifts the risk-reward profile toward greater dilution and financial fragility, reinforcing our WAIT stance. The capital raise signals that internal cash generation is insufficient to fund operations and remediation, and it raises the probability of covenant stress or further equity issuance. Our base-case and bull scenarios now require even stronger execution to overcome the incremental share overhang, while the bear case becomes more probable as the company burns cash and equity value.